Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)

Key Inclusion Criteria:

- Meets the following conditions:

- A clinical diagnosis of nonalcoholic fatty liver disease (NAFLD)

- Screening magnetic resonance imaging - proton density fat fraction (MRI-PDFF)
with ≥ 8% steatosis

- Screening magnetic resonance elastography (MRE) with liver stiffness ≥ 2.5
kilopascal (kPa) OR

- A historical liver biopsy within 12 months of screening consistent with NASH with
fibrosis, but not cirrhosis, and

- No documented weight loss > 5% between the date of the liver biopsy and
screening.

- Platelet count ≥ 150,000/mm^3

- Albumin ≥ 3.3 g/dL

- Serum creatinine ≤ upper limit of normal (ULN)

Key Exclusion Criteria:

- Pregnant or lactating females

- Alanine aminotransferase (ALT) > 5x upper limit of the normal range (ULN)

- Other causes of liver disease including autoimmune, viral, and alcoholic liver disease

- Cirrhosis of the liver

- Prior history of decompensated liver disease, including ascites, hepatic
encephalopathy, or variceal bleeding

- Body mass index (BMI) < 18 kg/m^2

- Uncontrolled diabetes mellitus (hemoglobin A1c > 9% at screening)

- International normalized ratio (INR) > 1.2 unless on anticoagulant therapy

- Total bilirubin > 1 x ULN, except with diagnosis of Gilbert's syndrome

Note: Other protocol defined Inclusion/Exclusion criteria may apply.